Corline Biomedical AB

Stockholm Stock Exchange CLBIO.ST

Corline Biomedical AB Price to Book Ratio (P/B) on January 14, 2025

Corline Biomedical AB Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Corline Biomedical AB 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Corline Biomedical AB 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Corline Biomedical AB average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: CLBIO.ST

Corline Biomedical AB

CEO	Dr. Henrik Nittmar Ph.D.
IPO Date	June 3, 2015
Location	Sweden
Headquarters	Lefflersgatan 5
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.

Key trends

Past 5 years